Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-3210 in Phenylketonuria
NCT06147856Phase 2Withdrawn
- Sponsor
- Moderna Inc
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of mRNA-3210 in phenylketonuria (PKU), sponsored by Moderna Inc. Primary endpoint: Number of Participants with Treatment Emergent Adverse Events. Planned start Mar 2024; status: withdrawn.
02
Drugs
mRNA-3210
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT06147856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06147856.